The global Immunohistochemistry (IHC) Market continues to accelerate, driven by rising cancer incidence, rapid adoption of automated pathology systems, and the growing demand for personalized medicine. Valued at US$3.31 billion in 2024 and rising to US$3.55 billion in 2025, the market is on track to reach US$5.14 billion by 2030, expanding at a robust CAGR of 7.6%.

With oncology becoming increasingly dependent on biomarker-based decision-making, IHC has evolved from a supportive tool to a frontline diagnostic technique—essential for tissue profiling, targeted therapy selection, and high-precision biomarker detection.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939

What’s Driving This Market? Key Growth Catalysts

1️⃣ Rising Global Cancer Burden

Cancer diagnoses continue to rise worldwide—and with them, the need for accurate, rapid, tissue-based analysis. IHC remains the gold standard for identifying protein biomarkers such as HER2, ALK, PD-L1, and many others that guide targeted therapy decisions.

2️⃣ Surge in Automation & Digital Pathology Integration

Modern labs are shifting to automated staining platforms, driven by demand for:

• Higher throughput
• Reproducible results
• Standardized workflows
• Reduced human error

Automation is also being paired with AI-powered image analysis, significantly improving diagnostic accuracy.

3️⃣ Personalized Medicine Gains Momentum

IHC is central to:

• Companion diagnostics (CDx)
• Tumor microenvironment analysis
• Drug-response prediction

As precision oncology expands, so do opportunities for IHC innovation.

Fastest-Growing Segment: IHC Kits (2025–2030)

The kits segment continues to outpace others due to an industry-wide shift toward:

• Closed-system reagents
• Pre-calibrated, ready-to-use formulations
• Single-vendor workflow consistency

Diagnostic labs prefer kits because they:

• Cut preparation time
• Minimize variability
• Improve throughput in routine and complex staining

This aligns perfectly with the global push toward standardized pathology workflows.

End User Spotlight: Hospitals & Diagnostic Laboratories Lead the Market

Hospitals and diagnostic labs represented the largest market share in 2024, driven by:

• Rising use of IHC for cancer, infectious diseases, and autoimmune disorders
• Increased establishment of in-house pathology labs
• Growing demand for fast, reliable diagnostic turnaround

As patient volumes rise and cancer care becomes more specialized, clinical labs are expanding IHC capabilities to support personalized treatment paths.

Regional Leader: Asia Pacific Dominates in 2024

The Asia Pacific region is emerging as a powerhouse for IHC growth, powered by:

Government healthcare investments

• China’s Healthy China 2030
• India’s Ayushman Bharat
• Expanded cancer screening programs

Rapidly increasing cancer prevalence

IARC reports show Asia contributes a major share of global cancer cases, fueling demand for advanced tissue diagnostics.

Growth of private diagnostic chains

India, Indonesia, Singapore, and Thailand lead in:

• Advanced pathology lab expansion
• Medical tourism
• CRO-driven clinical trials utilizing IHC

The region’s transformation into a global diagnostics hub continues to push the IHC market upward.

Latest Market Trends (2024–2025) Everyone Is Talking About

Trend 1: Multiplex IHC Takes Center Stage

Labs are adopting multiplex IHC (mIHC) to detect multiple biomarkers simultaneously—crucial for immuno-oncology research and tumor microenvironment mapping.

Trend 2: AI + IHC for Smart Diagnostics

AI algorithms integrated with digital pathology scanners are:

• Reducing interpretation variability
• Improving accuracy of biomarker scoring
• Enhancing workflow efficiency

Trend 3: Rise of CDx Partnerships

Pharma–diagnostics alliances are expanding to support:

• Targeted therapy approvals
• Personalized oncology treatment
• Companion IHC assays

Trend 4: Automation Rules the Lab

Fully automated platforms (e.g., next-gen stainers, closed-loop analyzers) are now essential due to:

• Staff shortages
• High test volumes
• The need for precision and reproducibility

Trend 5: Sustainability in Lab Operations

Eco-friendly reagents, waste-free systems, and energy-efficient instruments are gaining traction in pathology labs striving for greener workflows.

Competitive Landscape: Key Players Shaping the Future

Leading innovators include:

• F. Hoffmann-La Roche Ltd
• Danaher Corporation (Leica Biosystems)
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Bio-Rad Laboratories
• Bio-Techne
• Becton, Dickinson and Company
• Takara Bio
• Sino Biological
• Cell Signaling Technology

These companies are rapidly advancing automated systems, developing high-specificity monoclonal antibodies, and deepening collaborations for companion diagnostics and multiplex assays.

Company Highlights

Roche

• Strong pathology footprint
• BenchMark ULTRA PLUS system (2022)
• Ventana ALK (D5F3) CDx Assay success
• Innovation-led expansion across global markets

Danaher (Leica Biosystems)

• Key partnership with Navinci (2024) for advanced in situ PLA
• High R&D investment (US$1.5B in 2023)
• Expanding automated staining and imaging solutions

Agilent

• Strategic CDx partnerships (Incyte, Akoya Biosciences)
• 2022 Center of Excellence launched in India
• Rapid expansion in pathology solutions globally

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939